An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2

Monoclonal antibodies targeting the SARS‐CoV‐2 spike (S) neutralize infection and are efficacious for the treatment of COVID‐19. However, SARS‐CoV‐2 variants, notably sublineages of B.1.1.529/omicron, have emerged that escape antibodies in clinical use. As an alternative, soluble decoy receptors bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lianghui, Narayanan, Krishna K, Cooper, Laura, Chan, Kui K, Skeeters, Savanna S, Devlin, Christine A, Aguhob, Aaron, Shirley, Kristie, Rong, Lijun, Rehman, Jalees, Malik, Asrar B, Procko, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539395/
https://www.ncbi.nlm.nih.gov/pubmed/36094679
http://dx.doi.org/10.15252/emmm.202216109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539395/
https://www.ncbi.nlm.nih.gov/pubmed/36094679
http://dx.doi.org/10.15252/emmm.202216109

Ejemplares similares